{"answer":{"query":"xifaxan","resolved_as":"name","packages":8,"applications":["NDA021361"],"identity":{"application_numbers":["NDA021361"],"marketing_categories":["NDA"],"labelers":[{"text":"SALIX PHARMACEUTICALS, INC.","untrusted":true}],"dosage_forms":[{"text":"TABLET","untrusted":true}],"marketing_start":{"earliest":"2004-07-25","latest":"2010-05-01","packages_with_a_start_date":3}},"price":{"median_negotiated_over_nadac":null,"packages_compared":0,"packages_listed":8,"negotiated_price_ends":null,"rows":[{"ndc":"65649030103","name":{"text":"XIFAXAN","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"65649030104","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"65649030105","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"65649030141","name":{"text":"XIFAXAN","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"65649030203","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"65649030302","name":{"text":"XIFAXAN 550 TABS","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"65649030303","name":{"text":"XIFAXAN 550 TABS HUD","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"65649030304","name":{"text":"Xifaxan IBS-D 550mg 42ct Blister Pack","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null}],"negotiated_scheduled":{"thirty_day":1000,"effective":"2027-01-01"}},"generic_entry":[{"application":"NDA021361","date":"2029-10-02","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"8642573","productNo":"002"},"latest_patent_expiry":"2029-10-02","latest_exclusivity_expiry":"NOT_PROVIDED","dated_barriers":25,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":20,"exclusivities_listed":0,"fact_id":"b5727fef0187ab66f0f44337"}],"label_history":{"events_total":13,"non_cmc_events":9,"counts_by_class":{"LABELING":8,"EFFICACY":1},"cmc_events":4,"recent_non_cmc_events":[{"application":"NDA021361","submission_no":31,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2023-10-19","documents":[{"type":"Letter","date":"2023-10-20","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/021361Orig1s031ltr.pdf","untrusted":true}},{"type":"Label","date":"2023-10-24","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021361s031lbl.pdf","untrusted":true}}],"fact_id":"d49cd76283170b1184bc15af"},{"application":"NDA021361","submission_no":29,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2022-10-19","documents":[{"type":"Letter","date":"2022-10-20","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/021361Orig1s029ltr.pdf","untrusted":true}},{"type":"Label","date":"2022-10-21","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021361s029lbl.pdf","untrusted":true}}],"fact_id":"cc181a3eae28dac3fa522967"},{"application":"NDA021361","submission_no":25,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2020-11-06","documents":[{"type":"Letter","date":"2020-11-10","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/021361Orig1s025ltr.pdf","untrusted":true}},{"type":"Label","date":"2020-11-12","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021361s025lbl.pdf","untrusted":true}}],"fact_id":"c2eba1ac17d1dbcda396e97f"},{"application":"NDA021361","submission_no":23,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2017-12-18","documents":[{"type":"Label","date":"2017-12-19","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021361s023lbl.pdf","untrusted":true}},{"type":"Letter","date":"2017-12-20","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/021361Orig1s023ltr.pdf","untrusted":true}}],"fact_id":"b679b81f6d237399d1ed6037"},{"application":"NDA021361","submission_no":12,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2015-05-27","documents":[{"type":"Letter","date":"2015-05-28","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/021361Orig1s012ltr.pdf","untrusted":true}},{"type":"Label","date":"2015-05-29","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021361s012lbledt.pdf","untrusted":true}}],"fact_id":"18c9184c68497c98fb37191c"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":2,"te_code_counts":{"AB":1,"NOT_PROVIDED":1},"marketing_status_counts":{"Prescription":2},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA021361","product_no":"002","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"XIFAXAN","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"550MG","untrusted":true}},{"application":"NDA021361","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"XIFAXAN","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"200MG","untrusted":true}}]},"supply":{"fda_shortage_status_counts":{},"packages_with_a_termination_date":2,"next_package_termination_dates":[],"packages_with_future_termination_date":0,"termination_meaning":"manufacturer-reported last-lot expiry or withdrawal date of one package; other packages and generics can remain"},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"RIFAXIMIN","untrusted":true},"recruiting_interventional_count":24,"not_yet_recruiting_count":12,"by_phase":{"PHASE4":5,"PHASE2":5,"PHASE3":2,"EARLY_PHASE1":3,"NA":5,"PHASE1/PHASE2":1,"PHASE1":1,"PHASE2/PHASE3":2},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT06312683","title":{"text":"Rifaximin for the Secondary Prevention of Recurrent Pouchitis","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"University of North Carolina, Chapel Hill","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-23","start_date":"2024-07-01","link":{"text":"https://clinicaltrials.gov/study/NCT06312683","untrusted":true}},{"nct_id":"NCT07209371","title":{"text":"Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"Fred Hutchinson Cancer Center","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-08-17","start_date":"2026-01-22","link":{"text":"https://clinicaltrials.gov/study/NCT07209371","untrusted":true}},{"nct_id":"NCT07285785","title":{"text":"Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"Bausch Health Americas, Inc.","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-08-13","start_date":"2026-02-11","link":{"text":"https://clinicaltrials.gov/study/NCT07285785","untrusted":true}},{"nct_id":"NCT06443502","title":{"text":"A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Takeda","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-08-03","start_date":"2024-11-19","link":{"text":"https://clinicaltrials.gov/study/NCT06443502","untrusted":true}},{"nct_id":"NCT07683936","title":{"text":"Fecal Microbiota Transplantation for the Treatment of Refractory Hepatic Encephalopathy After TIPS Surgery","untrusted":true},"phase":["EARLY_PHASE1"],"sponsor":{"text":"Air Force Military Medical University, China","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-07-06","start_date":"2026-06-01","link":{"text":"https://clinicaltrials.gov/study/NCT07683936","untrusted":true}}],"fact_id":"b779ad2992bc74c92aa5852e"}]},"spending":{"reported_under":{"generic":{"text":"Rifaximin","untrusted":true},"brand":{"text":"Xifaxan","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":844562189.07,"claims":360725,"beneficiaries":83804,"average_spending_per_claim_usd":2341.2909809,"fact_id":"bfb5935b2d68a2a60624d54a"},{"year":2021,"gross_spending_usd":890298769.04,"claims":357681,"beneficiaries":87233,"average_spending_per_claim_usd":2489.0859985,"fact_id":"36e10548cb52cc6b7f29582a"},{"year":2022,"gross_spending_usd":969541694.2,"claims":360882,"beneficiaries":88758,"average_spending_per_claim_usd":2686.5892292,"fact_id":"35691dae422f3db80ec0aceb"},{"year":2023,"gross_spending_usd":1090110101.4,"claims":384018,"beneficiaries":96011,"average_spending_per_claim_usd":2838.6953253,"fact_id":"25f737217a5d5452e9b22f95"},{"year":2024,"gross_spending_usd":1158111408.6,"claims":416690,"beneficiaries":104805,"average_spending_per_claim_usd":2779.3117391,"fact_id":"72024894d4c5856598d72ce4"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"orphan_designation":{"ingredients":[{"ingredient":{"text":"Rifaximin; rifaximin","untrusted":true},"designation_count":2,"approved_count":1,"recent":[{"designated":"2020-10-28","use":{"text":"treatment of sickle cell disease","untrusted":true},"status":"Designated","sponsor":{"text":"Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)","untrusted":true},"approved":false},{"designated":"1998-02-10","use":{"text":"Treatment of hepatic encephalopathy","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Salix Pharmaceuticals, Inc.","untrusted":true},"approved":true}],"read_on":"2026-11-07T12:00:00.000Z","fact_id":"de6e3c21e9ec7a16dbd0bf42"}],"reading":"a designation is not an approval and not a statement that the drug treats the condition; status is the FDA database's own"},"medicaid_state_utilization":{"year":2024,"states_with_data":51,"all_states_medicaid_reimbursed_usd":405231426.45,"all_states_medicaid_paid_prescriptions":150114,"top_states":[{"state":"CA","medicaid_paid_prescriptions":21801,"medicaid_reimbursed_usd":64213621.93,"total_reimbursed_usd":64515111.41,"packages":3,"covers":"fee_for_service_only","fact_id":"392c8bce42ff946604da2741"},{"state":"NY","medicaid_paid_prescriptions":14909,"medicaid_reimbursed_usd":41907052.02,"total_reimbursed_usd":42399171.32,"packages":1,"covers":"all_record_types","fact_id":"93d40673742f9db390459c8d"},{"state":"OH","medicaid_paid_prescriptions":7677,"medicaid_reimbursed_usd":19658805.71,"total_reimbursed_usd":19757250.06,"packages":2,"covers":"all_record_types","fact_id":"7c488e52f8e638130aa5240d"},{"state":"PA","medicaid_paid_prescriptions":6538,"medicaid_reimbursed_usd":17124229.55,"total_reimbursed_usd":17297007.35,"packages":1,"covers":"all_record_types","fact_id":"37a9cca9f0ace6a7420171c0"},{"state":"AZ","medicaid_paid_prescriptions":5557,"medicaid_reimbursed_usd":15297086.11,"total_reimbursed_usd":15446954.08,"packages":2,"covers":"fee_for_service_only","fact_id":"37eef1e0f114d6bf24a3051a"},{"state":"KY","medicaid_paid_prescriptions":6524,"medicaid_reimbursed_usd":14747441.96,"total_reimbursed_usd":14747441.96,"packages":2,"covers":"all_record_types","fact_id":"b595337f1efc2f26b7af9f12"},{"state":"IL","medicaid_paid_prescriptions":5566,"medicaid_reimbursed_usd":13604627.7,"total_reimbursed_usd":13650353.4,"packages":1,"covers":"all_record_types","fact_id":"5c9891e305bba5b487e995e3"},{"state":"MI","medicaid_paid_prescriptions":4934,"medicaid_reimbursed_usd":12998611.68,"total_reimbursed_usd":13009993.97,"packages":1,"covers":"all_record_types","fact_id":"2697d0f1b6c8b5ff4ac633db"},{"state":"WI","medicaid_paid_prescriptions":4392,"medicaid_reimbursed_usd":12158894.58,"total_reimbursed_usd":12304641.68,"packages":2,"covers":"all_record_types","fact_id":"7442b38d1585a2af24e888b6"},{"state":"MA","medicaid_paid_prescriptions":4807,"medicaid_reimbursed_usd":12142153.16,"total_reimbursed_usd":12256191.49,"packages":2,"covers":"fee_for_service_only","fact_id":"18301de5bb6e93d3b203270e"}],"unlabelled_state_code_xx":{"medicaid_paid_prescriptions":153282,"medicaid_reimbursed_usd":411349999.3,"note":"the source uses the code XX without defining it; it is reported here and never added to a state"},"built_from_facts":62,"facts_fee_for_service_only":12,"older_year_facts_not_used":0,"dataset":"State Drug Utilization Data 2024","read_on":"2026-11-07T23:59:45.983Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"16c38a5ae8142ca1a676e25a","field":"ndc.listing","entity":"ndc:65649030103"},{"fact_id":"1031508272f580d3c2e5cadb","field":"ndc.listing","entity":"ndc:65649030302"},{"fact_id":"2168a5bed2fd2d296cc49cfe","field":"ndc.listing","entity":"ndc:65649030303"},{"fact_id":"b5727fef0187ab66f0f44337","field":"drug.generic_entry_earliest","entity":"application:NDA021361"},{"fact_id":"595dea0e5338a6c5d1f1864b","field":"drug.patent","entity":"application:NDA021361"},{"fact_id":"d49cd76283170b1184bc15af","field":"drug.label_event","entity":"application:NDA021361"},{"fact_id":"cc181a3eae28dac3fa522967","field":"drug.label_event","entity":"application:NDA021361"},{"fact_id":"c2eba1ac17d1dbcda396e97f","field":"drug.label_event","entity":"application:NDA021361"},{"fact_id":"b679b81f6d237399d1ed6037","field":"drug.label_event","entity":"application:NDA021361"},{"fact_id":"18c9184c68497c98fb37191c","field":"drug.label_event","entity":"application:NDA021361"},{"fact_id":"928da55143353cd26acdb026","field":"drug.te_code","entity":"application:NDA021361"},{"fact_id":"be70deb5bfc88d7854979dab","field":"drug.marketing_status","entity":"application:NDA021361"},{"fact_id":"e02242ab51850855c92fda31","field":"drug.marketing_status","entity":"application:NDA021361"},{"fact_id":"b779ad2992bc74c92aa5852e","field":"drug.trial_access","entity":"drug:rifaximin"},{"fact_id":"bfb5935b2d68a2a60624d54a","field":"drug.partd_spending","entity":"drug:rifaximin|xifaxan"},{"fact_id":"36e10548cb52cc6b7f29582a","field":"drug.partd_spending","entity":"drug:rifaximin|xifaxan"},{"fact_id":"35691dae422f3db80ec0aceb","field":"drug.partd_spending","entity":"drug:rifaximin|xifaxan"},{"fact_id":"25f737217a5d5452e9b22f95","field":"drug.partd_spending","entity":"drug:rifaximin|xifaxan"},{"fact_id":"72024894d4c5856598d72ce4","field":"drug.partd_spending","entity":"drug:rifaximin|xifaxan"},{"fact_id":"de6e3c21e9ec7a16dbd0bf42","field":"drug.orphan_designation","entity":"drug:rifaximin"},{"fact_id":"392c8bce42ff946604da2741","field":"ndc.medicaid_state_utilization","entity":"ndc_state:65649030302:CA"},{"fact_id":"93d40673742f9db390459c8d","field":"ndc.medicaid_state_utilization","entity":"ndc_state:65649030302:NY"},{"fact_id":"7c488e52f8e638130aa5240d","field":"ndc.medicaid_state_utilization","entity":"ndc_state:65649030302:OH"},{"fact_id":"37a9cca9f0ace6a7420171c0","field":"ndc.medicaid_state_utilization","entity":"ndc_state:65649030302:PA"},{"fact_id":"37eef1e0f114d6bf24a3051a","field":"ndc.medicaid_state_utilization","entity":"ndc_state:65649030302:AZ"},{"fact_id":"b595337f1efc2f26b7af9f12","field":"ndc.medicaid_state_utilization","entity":"ndc_state:65649030302:KY"},{"fact_id":"5c9891e305bba5b487e995e3","field":"ndc.medicaid_state_utilization","entity":"ndc_state:65649030302:IL"},{"fact_id":"2697d0f1b6c8b5ff4ac633db","field":"ndc.medicaid_state_utilization","entity":"ndc_state:65649030302:MI"},{"fact_id":"7442b38d1585a2af24e888b6","field":"ndc.medicaid_state_utilization","entity":"ndc_state:65649030302:WI"},{"fact_id":"18301de5bb6e93d3b203270e","field":"ndc.medicaid_state_utilization","entity":"ndc_state:65649030302:MA"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price.ratio","reason":"no package has both a brand-class NADAC price and a negotiated price in force"},{"code":"NO_DATA","field":"recalls","reason":"no FDA enforcement report naming a package of these applications is recorded"},{"code":"NO_DATA","field":"assistance_and_offers","reason":"no assistance program lists this drug and no manufacturer offer naming it is recorded; that does not mean none exists"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}